Prostate Cancer Metastatic Clinical Trial
— METROOfficial title:
Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer
The study is an open label, multi-centre, randomized phase III study. The patients will be randomised in a 1:1 ratio to treatment consisting of - Arm A: MD-SBRT in addition to standard treatment - Arm B: Standard treatment Study population: Patients with hormone sensitive prostate cancer (HSPC) with oligometastatic disease detected by PSMA-PET/DT. This includes patients with de novo oligometastatic HSPC and recurrent HSPC after primary RT or prostatectomy. Primary endpoint: Failure free survival Secondary endpoints: - Predictive value of investigated biomarkers in blood and imaging - Acute and late toxicity after MD-SBRT - PROM at 3 months, 1, 3 and 5 years - Castration resistant prostate cancer, CRPC - Overall survival - Differences in outcome between patients by strata Stratification: To avoid imbalance between treatment arms the minimisation method will be used to achieve balance between de novo oligo-metastatic and oligo-recurrent patients, as well as treatment site. Safety evaluation: Adverse events and side effects graded according to CTCAE v5.0 will be collected every 6th month. Serious Adverse Events are to be reported within 24 hours throughout the study duration. Statistical methods: Survival endpoints will be calculated using the Kaplan-Meier method with differences compared using the stratified log-rank test. Randomization time is set as baseline time. Pre-planned subgroup analysis will occur based on pre-specified stratification variables. A Cox multivariable regression model will be used to determine factors predictive of survival. Safety analysis will be performed with Mann-Whitney U-test or Fishers exact test. Criteria for evaluation: Per protocol (patients that have started study treatment) and Intention to treat (all included patients). Planned sample size: 118 patients Analysis plan: The primary end point will be analysed after pre-specified number of events have occurred. All patients randomised to SBRT will be followed minimum 60 months for toxicity. Safety analysis of acute toxicity will take place after median follow up of 6 months. Safety analysis of late toxicity will be analysed after study closure. Duration of the study: Three to five years inclusion. 72 months of follow-up after randomization of the last patient.
Status | Recruiting |
Enrollment | 118 |
Est. completion date | December 2031 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Histologically confirmed prostate cancer (ICD-O-3 C61) 2. WHO/ECOG performance status 0-1 3. 1-3 skeletal or extra pelvic lymph node metastases detected by PSMA-PET/CT in i. de novo prostate cancer or ii. PSA-relapse after definitive RT or prostatectomy 4. Willing and able to provide informed consent- Exclusion Criteria: 1. Castration resistant prostate cancer (progression with castrate levels of testosterone <20ng/dL) 2. Any treatment known to affect PSA (including ADT) for prostate cancer within 6 months (exception: ADT started due to oligometastatic disease within 2 weeks of study entry) 3. Patient eligible for other treatment (e.g., early docetaxel) than standard treatment described in the protocol as judged by treating physician 4. Life expectancy <3 years by any reason, including concomitant or previous malignancies 5. Previous radiotherapy or surgery that may interfere with the planned treatment (including intra-prostatic recurrence if previous RT to the prostate) 6. > 3 PSMA-PET/CT positive target lesions (excluding the prostate in de novo patients or prostate bed post radical prostatectomy) 7. PSMA-PET verified metastases other than skeletal or lymph nodes 8. Metastases in base of scull and/or calotte 9. Any target lesions not treatable with image guided RT (IGRT) due to overlap with previous RT fields or exceeded dose constraint to OAR(s) as specified in study protocol |
Country | Name | City | State |
---|---|---|---|
Sweden | Ryhovs county hospital | Jönköping | |
Sweden | Karolinska University Hospital | Stockholm | |
Sweden | Umeå University hospital | Umeå | Umea |
Lead Sponsor | Collaborator |
---|---|
Umeå University | Karolinska University Hospital, Region Jönköping County, Region Örebro County, Region Skane, Stockholm South General Hospital, University Hospital, Umeå, Vastra Gotaland Region |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | outcome according to strata | all outcomes 1-6 will be analysed by stata; primary or recurrent oligometastatic prostate cancer and study site (for inclusion) | Throughout the study duration (72 months of follow up for last patient included.) | |
Primary | Failure free survival | Time from randomisation to progressive disease. Progression is defined as 2 consecutive rises in blood PSA. PSA will be collected every third month and registered in the electronic case report form. | Throughout the study duration (72 months of follow up for last patient included.) | |
Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5. | Side effects according to Common Terminology Criteria for Adverse Events version 5, CTCAE v5 will be collected at baseline, 3 and 6 months after randomisation for all organs at risk within 3 cm from the SBRT-target in the electronic case report form. Adverse events are scored from 0 (none) to 5 (fatal) in the electronic case report form. We will report the number of patients with no reported side effects as well as the number of patients scoring 1, 2, 3, 4 and 5 assessed by CTCAE v5. | Until 6 months after randomisation | |
Secondary | Number of participants with treatment-related serious adverse events as assessed by CTCAE v5. | Side effects grade 4 or higher according to Common Terminology Criteria for Adverse Events version 5, CTCAE v5 will be collected every 6th months after randomisation for all organs at risk within 3 cm from the SBRT-target. Adverse events are scored from 0 (none) to 5 (fatal) are collected in the electronic case report form. We will report the number of patients with no reported side effects as well as the number of patients scoring 1, 2, 3, 4 and 5 assessed by CTCAE v5. | Throughout the study duration (72 months of follow up for last patient included.) | |
Secondary | Outcome prediction | Blood samples will be collected to enable evaluation of circulating biomarkers in relation to patient response to treatment at baseline, 1 and 3 months after randomisation, and at progression. Specifically, plasma will be sampled and circulating tumor cells and platelets will be further isolated. Imaging parameters from the baseline PSMA-PET/CT will also be evaluated in relation to outcome. | Throughout the study duration (72 months of follow up for last patient included.) | |
Secondary | Patient reported quality of life assessed by EORTC-QLQ 30 | Patients will fill out a cross validated self registration questionnaire; European Organistaion for Research and Treatment of Cancer Quality of Life Questionnaire, EORTC QLQ 30, at baseline, 3 months, year 1, 3 and 5. The questionnaire consists of 28 statements that are to be graded from 1 (not at all) to 4 (very well) according to how well they correspond to the patients perception. EORTC QLQ30 also ask for the patient to score their overall sense of 1)health and 2)quality of life on a scale from 1 (very poor) to 7 (excellent). | Throughout the study duration (72 months of follow up for last patient included.) | |
Secondary | Overall survival | Death due to any cause | Throughout the study duration (72 months of follow up for last patient included.) | |
Secondary | Castration resistent prostate cancer, CRPC | 2 consecutive rises in blood PSA with castrate levels of testosterone. PSA will be collected every third month and registered in the electronic case report form. Testosterone will be collected if a rise in PSA level is detected. | Throughout the study duration (72 months of follow up for last patient included.) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Suspended |
NCT05361915 -
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05067140 -
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03646162 -
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03413995 -
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations
|
Phase 2 | |
Not yet recruiting |
NCT06461689 -
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
|
||
Recruiting |
NCT05078151 -
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
|
N/A | |
Recruiting |
NCT03507595 -
Evaluation of the Metastasis and Recurrence of Prostate Cancer
|
||
Completed |
NCT03362359 -
Ga-68-PSMA-11 in High-risk Prostate Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04116775 -
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
|
Phase 2 | |
Completed |
NCT03223727 -
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
|
||
Recruiting |
NCT04086290 -
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04983628 -
Molecular Profiling in Prostate Cancer
|
||
Active, not recruiting |
NCT03414437 -
Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)
|
||
Completed |
NCT02485691 -
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
|
Phase 4 | |
Completed |
NCT03693742 -
MSG Use With 18F-DCFPyL PET/CT Imaging
|
N/A | |
Completed |
NCT01322490 -
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 | |
Completed |
NCT03739684 -
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05655715 -
Checkpoint Inhibitors and SBRT for mCRPC
|
Phase 2 |